Research programme: ataxia therapy - NeuroSearchAlternative Names: NSD-801
Latest Information Update: 04 Dec 2013
At a glance
- Originator NeuroSearch
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Dyskinesias
Most Recent Events
- 28 Sep 2011 Research programme: ataxia therapy - NeuroSearch is available for licensing as of 28 Sep 2011. http://neurosearch.com
- 11 Jan 2011 Preclinical trials in Dyskinesia in Denmark (unspecified route)